Intracardiac Echocardiography: Why Medtronic Made Two Bets on the Same Technology

On June 3rd, Medtronic revealed a pair of investments that caught the attention of the electrophysiology market. The companies are located on opposite sides of the world, but they share a common focus: intracardiac echocardiography (ICE) catheters.

One investment went to California-based Beluga Medical. The other went to Shenzhen-based CardioACC. Financial terms were not disclosed, but the significance of the deals extends well beyond the size of the checks.

Together, the investments offer insight into where Medtronic believes cardiac ablation is heading and how it plans to strengthen the Affera platform as competition intensifies across electrophysiology.

Why Intracardiac Echocardiography Has Become a Strategic Priority

Medtronic has been clear about its intentions. The company plans to integrate ICE capabilities into its Affera mapping and ablation ecosystem.

Rebecca Seidel, president of Medtronic’s Cardiac Ablation Solutions business, described ICE catheters as a core component of modern ablation procedures and indicated that the Affera platform will evolve to incorporate the technology. The investments were positioned as another step in expanding Medtronic’s leadership position in electrophysiology.

That matters because while pulsed-field ablation continues to dominate headlines, imaging remains fundamental to every procedure. Physicians rely on ICE to visualize anatomy, guide catheter placement, confirm transseptal access, and monitor for complications during treatment.

The market opportunity reflects that growing importance:

• The ICE market was valued at approximately $1.1 billion in 2025 and is projected to reach roughly $3.3 billion by 2035.

• The broader atrial fibrillation device market reached $12.9 billion in 2025 and continues to grow at a low double-digit rate.

• An estimated 6.7 million Americans were living with AFib in 2024, with projections exceeding 8 million by 2030.

Although most procedures still rely on traditional 2D imaging, the next phase of growth is increasingly centered on 4D visualization. These systems provide live volumetric imaging from within the heart, delivering views that approach transesophageal echocardiography quality without requiring general anesthesia.

As a result, ICE is expanding beyond standard ablation procedures into higher-value structural heart interventions and left atrial appendage applications.

Several major players already have commercial products in the category, including:

• Johnson & Johnson MedTech (CARTOSOUND)

• Siemens Healthineers (AcuNav Volume)

• Philips (VeriSight Pro)

Prior to these investments, Medtronic lacked a competitive ICE catheter offering. The combination of CardioACC and Beluga Medical changes that position.

CardioACC already markets both 2D and 4D systems, while Beluga Medical is developing a next-generation platform that remains in the pre-market stage. Together, they provide exposure to today’s commercial opportunities as well as future technology development.

This blog is originally published here: https://www.lifesciencemarketresearch.com/insights/intracardiac-echocardiography-why-medtronic-made-two-bets-on-the-same-technology